Cargando…
AB056. Cytoreductive radical prostatectomy for men with oligo-metastatic prostate cancer
BACKGROUND: To present our preliminary surgical experience with cytoreductive radical prostatectomy for patients with oligometastatic prostate cancer. METHODS: Ten selective cases with oligometastatic prostate cancer diagnosed by bone scan and biopsy of prostate underwent cytoreductive radical prost...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565527/ http://dx.doi.org/10.21037/tau.2017.s056 |
_version_ | 1783258393990922240 |
---|---|
author | Liu, Shengjie Wang, Jiangyi Li, Teng Hong, Baoan Gong, Kan |
author_facet | Liu, Shengjie Wang, Jiangyi Li, Teng Hong, Baoan Gong, Kan |
author_sort | Liu, Shengjie |
collection | PubMed |
description | BACKGROUND: To present our preliminary surgical experience with cytoreductive radical prostatectomy for patients with oligometastatic prostate cancer. METHODS: Ten selective cases with oligometastatic prostate cancer diagnosed by bone scan and biopsy of prostate underwent cytoreductive radical prostatectomy. The operating time, estimated blood loss and perioperative complication were recorded and evaluated. Follow up studies were performed with an evaluation for postoperative PSA level and the status of the urinary voiding. RESULTS: The mean age was 65.1 years (range, 55–78 years), initial PSA level was 70.27 ng/mL (range, 8.56–280.0 ng/mL), biopsy Gleason score was 8 (range, 6–9), Preoperative clinical stage 1 case T4N0M1, 3 cases T3N1M1, 4 cases T3N0M1, 2 cases T2N0M1. All the operations were successfully performed. The total operative time range was 110–260 min with mean time of 200 min. The blood loss was 85–350 mL with mean 140 mL and no blood transfusion was required. The catheter was removed after a mean [range] of 14 [9–16] days. No intra-operative complications occurred. Eight patients had positive surgical margins. The mean [range] hospital stay was 7 [3–15] days after surgery. All the cases were continent after removal of the catheter. No cases demonstrated vesicourethral stricture. All ten patients had decreased PSA after operation 6 weeks. CONCLUSIONS: Cytoreductive radical prostatectomy for patients with oligometastatic prostate cancer could be safe, effective, and appropriate. Cytoreductive radical prostatectomy might be a treatment option in the multimodal management of oligo-metastatic prostate cancer. |
format | Online Article Text |
id | pubmed-5565527 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-55655272017-09-01 AB056. Cytoreductive radical prostatectomy for men with oligo-metastatic prostate cancer Liu, Shengjie Wang, Jiangyi Li, Teng Hong, Baoan Gong, Kan Transl Androl Urol Printed Abstracts BACKGROUND: To present our preliminary surgical experience with cytoreductive radical prostatectomy for patients with oligometastatic prostate cancer. METHODS: Ten selective cases with oligometastatic prostate cancer diagnosed by bone scan and biopsy of prostate underwent cytoreductive radical prostatectomy. The operating time, estimated blood loss and perioperative complication were recorded and evaluated. Follow up studies were performed with an evaluation for postoperative PSA level and the status of the urinary voiding. RESULTS: The mean age was 65.1 years (range, 55–78 years), initial PSA level was 70.27 ng/mL (range, 8.56–280.0 ng/mL), biopsy Gleason score was 8 (range, 6–9), Preoperative clinical stage 1 case T4N0M1, 3 cases T3N1M1, 4 cases T3N0M1, 2 cases T2N0M1. All the operations were successfully performed. The total operative time range was 110–260 min with mean time of 200 min. The blood loss was 85–350 mL with mean 140 mL and no blood transfusion was required. The catheter was removed after a mean [range] of 14 [9–16] days. No intra-operative complications occurred. Eight patients had positive surgical margins. The mean [range] hospital stay was 7 [3–15] days after surgery. All the cases were continent after removal of the catheter. No cases demonstrated vesicourethral stricture. All ten patients had decreased PSA after operation 6 weeks. CONCLUSIONS: Cytoreductive radical prostatectomy for patients with oligometastatic prostate cancer could be safe, effective, and appropriate. Cytoreductive radical prostatectomy might be a treatment option in the multimodal management of oligo-metastatic prostate cancer. AME Publishing Company 2017-08 /pmc/articles/PMC5565527/ http://dx.doi.org/10.21037/tau.2017.s056 Text en 2017 Translational Andrology and Urology. All rights reserved. |
spellingShingle | Printed Abstracts Liu, Shengjie Wang, Jiangyi Li, Teng Hong, Baoan Gong, Kan AB056. Cytoreductive radical prostatectomy for men with oligo-metastatic prostate cancer |
title | AB056. Cytoreductive radical prostatectomy for men with oligo-metastatic prostate cancer |
title_full | AB056. Cytoreductive radical prostatectomy for men with oligo-metastatic prostate cancer |
title_fullStr | AB056. Cytoreductive radical prostatectomy for men with oligo-metastatic prostate cancer |
title_full_unstemmed | AB056. Cytoreductive radical prostatectomy for men with oligo-metastatic prostate cancer |
title_short | AB056. Cytoreductive radical prostatectomy for men with oligo-metastatic prostate cancer |
title_sort | ab056. cytoreductive radical prostatectomy for men with oligo-metastatic prostate cancer |
topic | Printed Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565527/ http://dx.doi.org/10.21037/tau.2017.s056 |
work_keys_str_mv | AT liushengjie ab056cytoreductiveradicalprostatectomyformenwitholigometastaticprostatecancer AT wangjiangyi ab056cytoreductiveradicalprostatectomyformenwitholigometastaticprostatecancer AT liteng ab056cytoreductiveradicalprostatectomyformenwitholigometastaticprostatecancer AT hongbaoan ab056cytoreductiveradicalprostatectomyformenwitholigometastaticprostatecancer AT gongkan ab056cytoreductiveradicalprostatectomyformenwitholigometastaticprostatecancer |